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to the extremes of ranges, and start date for length of survival: method 
1. progression after second line therapy or three weeks post last dose of 
chemo for control group and start date of erlotinib for treatment group; 
method 2. last date of second line therapy for both groups. 
75 control and 70 erlotinib patients were included in the analysis. 
Results are presented in the table. The Incremental Cost-Effectiveness 
Ratio (ICER) was $28,516 per life-year-gained under method 1, and 
$17,632 under method 2. The erlotinib group had similar one year OS 
compared to literature (36 vs. 31%).
Method 1: Parameter Controls (N=75) Erlotinib (N=70)
Area under curve (months) 3.86 7.91
p-value (log-rank test) <0.001
Median Survival months (95% CI) 2.56 (2.04-4.8) 4.73 (2.89-14.7)
1-year OS % (95% CI) 0.04 (0.01-0.13) 0.36 (0.24-0.53)
Mean drug cost $CDN/patient (range) 7,560 (1,445-26,710) 17,184 (2,660-58,539)
ICER $28,516/LYG
Method 2: Parameter
Area under curve 5.35 11.90
p-value (log-rank test) <0.001
Median Survival months (95% CI) 3.35 (2.53-6.38) 8.61 (7.56-19.99)
1-year OS % (95% CI) 0.11 (0.06-0.21) 0.45 (0.34-0.60)
ICER $17,632/LYG
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Background: Epidermal Growth Factor Receptor tyrosine kinase 
Inhibitors (EGFRTKI) have proven selective efﬁcacy in advanced 
NSCLC where potential predictors of response have been studied. 
Their role in early stage NSCLC has not been established.
Purpose: Using pharmacodynamic sampling pre- and post-therapy 
with geﬁtinib, 1) to assess the impact of geﬁtinib on EGFR intracellular 
signaling pathways; and 2) to assess response and toxicity rates after 
preoperative geﬁtinib (Iressa, AstraZeneca)
Methods: Stage I NSCLC patients received geﬁtinib (Iressa, 250 
mg/day) for 28 days followed by mediastinoscopy and surgical resec-
tion in a single arm open label study. Tumor response was evaluated by 
RECIST. Pre-treatment (snap frozen, core needle biopsy) and post-
operative (snap frozen and formalin ﬁxed, surgical specimen) tumor 
samples were obtained. Mutation analysis of EGFR exons 19 and 21 
was performed by PCR fragment length analysis and direct sequencing. 
EGFR, its phospho-isoforms and intracellular signaling pathways were 
analyzed by immunohistochemistry 
Results: Thirty-four patients have completed treatment. Mean fol-
low-up is 4.7 months (2.3-11.6). Sixty-ﬁve percent of cases were 
adenocarcinomas, 21% squamous cell, 12% pure BAC, and 3% large 
cell carcinoma. Fifty percent were active smokers, 38% former smok-
ers and 12% never smoked. No unexpected toxicities during geﬁtinib 
treatment were seen. Five patients had serious adverse events within 
30 days post-surgery (2 pulmonary infections, 2 prolonged air leaks, 1 
pulmonary embolism). Four (12%) patients had exon 19 deletions and 
two (6%) had exon 21 point mutations. Two pts with exon 19 deletions 
had a partial response (PR) to treatment, the others stable disease (SD). 
One pt with exon 21 point mutation had a PR, the other SD. In patients 
without mutation, 1 had a PR, 22 SD, and 3 PD on therapy. The overall 
response rate was 11.7% in the sample. No differences in mutations 
were detected comparing pre- and post-treatment specimens. 
By univariate analyses (Fisher’s Exact Test and t-Test), presence of ﬁ-
brosis in surgically resected specimens was associated with any EGFR 
mutation (p=0.002) and exon 19 deletion alone (p=0.008). Female gen-
der (p=0.007), never-smoking status (0.029), BAC (p=0.009), EGFR 
mutation (p=0.002), and exon 19 deletion (p=0.023) were associated 
with a reduction in maximum tumor diameter, but only any EGFR mu-
tation (p=0.016) was associated with RECIST response. In multivariate 
analysis, the only variable associated with tumor reduction, RECIST re-
sponse and ﬁbrosis was the presence of any EGFR mutation, (p=0.016). 
Preliminary analysis suggests non responders are not experiencing 
complete EGFR inhibition in vivo. Additional measures associated with 
response are under assessment. 
Conclusions: Geﬁtinib can be administered safely preoperatively in 
early NSCLC. EGFR mutation analysis is feasible on percutaneous 
biopsies. Short-term EGFRTKI treatment does not result on changes in 
mutation proﬁle. Comparison of pre- and post-therapy tumor samples 
may allow additional understanding of EGFR TKI resistance and facili-
tate patient selection.
Overall, response rates and predictors of response in early stage 
NSCLC are not different from advanced disease.
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Background: The phase III randomised BR.21 study demonstrated 
that in patients with relapsed advanced NSCLC, erlotinib (Tarceva®) 
improved survival and prolonged time to symptom deterioration 
compared with placebo (Shepherd et al. NEJM 2005;353:123-132). 
Erlotinib was well tolerated, with rash and diarrhoea the most com-
mon adverse events (AEs), both being generally mild to moderate in 
severity. The global, open-label TRUST study was initiated to provide 
erlotinib access to patients with advanced NSCLC. Data are reported 
here for the E/SE subgroup.
Methods: Eligible patients with stage IIIB/IV NSCLC had failed previ-
ous chemotherapy for advanced disease (≤2 prior regimens) or were 
unsuitable for chemotherapy. Erlotinib was administered orally 150mg/
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day until disease progression or unacceptable toxicity. Dose reductions 
(50mg increments) were allowed as required. The NCI-CTC v3.0 was 
used to assess toxicities, including: incidence and grade of erlotinib-
related rash; serious AEs (SAEs) and treatment-related SAEs; and AEs 
leading to treatment withdrawal. Other treatment-related AEs were 
reported if they were not included on a list of 15 pre-speciﬁed AEs in 
the study protocol (rash; pruritis; dry skin; diarrhea; nausea; vomiting; 
stomatitis; abdominal pain; fatigue; dyspnoea; cough; anorexia; infec-
tion; conjunctivitis; and keratoconjunctivitis sicca).
Results: 885 patients were included in the analysis at the data cut-off 
(20/11/06) from Taiwan (n=297), mainland China (n=248), Hong Kong 
(n=160), South Korea (n=146), Thailand (n=30), Indonesia (n=2) and 
Malaysia (n=2). The median age was 61 years (range 22-95). Patient 
characteristics included: male 55%, female 45%; stage IIIB 20%, stage 
IV 79% (no data 1%); ECOG PS 0 15%, PS 1 67%, PS 2 14%, PS 3 
4%; non-smoker 52%, ever-smoker 47% (no data <1%); adenocarcino-
ma 68%, squamous-cell carcinoma 19%, other 13%; erlotinib 1st line 
11%, 2nd line 55%, 3rd line 33%, other <1%. Data on the occurrence 
of rash were available for 882 patients, 83% of whom experienced rash, 
mostly grade 1/2 (88% of those with rash). Adverse event (AE) safety 
data were available for 598 patients, 54% of whom experienced at least 
one AE. 19 patients (3%) had treatment-related SAEs, most commonly 
gastrointestinal (GI) disorders (1%), including abdominal pain (n=2), 
diarrhoea (n=5) and gastric ulcer haemorrhage (n=1). 17% of patients 
had at least one other treatment-related AE that was not pre-speciﬁed 
(3% had at least one grade 3/4 event); mucosal inﬂammation occurred 
in 3% of patients (<1% grade 3/4), but no other single event occurred 
in more than 2% of patients. Treatment-related interstitial lung disease 
(ILD; grade 2) was suspected in one patient, but this event was not re-
ported as an SAE and did not lead to treatment withdrawal; the patient 
continued on erlotinib until disease progression. 18 patients (3%) had 
at least one treatment-related AE leading to withdrawal of erlotinib; the 
most common such events were rash (4 patients), diarrhoea (3 patients) 
and pneumonitis (3 patients). Among 589 patients with available data, 
76 (13%) required dose reduction due to a treatment-related event, 
mainly rash (n=57). Efﬁcacy data will be presented.
Conclusions: Safety data for the E/SE Asian patient population in 
TRUST support the safety proﬁle of erlotinib seen in clinical trials. The 
incidence of ILD and ILD-like events is <1%, which is in-keeping with 
what has been seen with erlotinib universally. In the ‘real-life’ clinical 
setting, erlotinib is well tolerated, with full therapeutic doses adminis-
tered to the majority of patients. 
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Implications of tumour cavitation on response assessment in 
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Inhibitors in combination with platinum-based chemotherapy for 
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conducted by the National Cancer Institute of Canada Clinical 
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Introduction: Inhibition of angiogenesis has shown promise in a 
variety of solid tumours. In NSCLC, the addition of bevacizumab to 
platinum-based doublet chemotherapy has led to a modest improve-
ment in survival in highly selected patients (pts). Antiangiogenic agents 
may be associated with cavitation of tumours, felt possibly due to 
ischemic necrosis; in the lung, this may lead to air-trapping and subse-
quent enlargement of the target lesion, which may lead to difﬁculties 
with assigning overall best response as well as date of progression. The 
NCIC CTG has conducted a number of studies of VEGFR inhibitors as 
single agent or in conjunction with standard chemotherapy regimens in 
a number of tumour types, including NSCLC.
Methods: Two phase I studies enrolled ﬁrst line NSCLC patients to es-
calating doses of a VEGFR inhibitor in combination with either standard 
carboplatin / paclitaxel or cisplatin / gemcitabine regimens. The control 
arm of a large phase II/III study of the same regimen of carboplatin and 
paclitaxel with identical entry criteria was used as a historical control. In 
all trials, response was assessed by RECIST every second cycle, radiol-
ogy reports were reviewed centrally conﬁrming response, progression 
and evidence of cavitation, while an independent response review has 
been conducted for one phase I study, where possible for all patients 
with cavitation noted in radiology reports, and is ongoing for the second 
phase I study. Pts showing cavitation had, in addition, an ‘exploratory’ 
response assessment in which the longest diameter of the cavity was 
subtracted from the total size of the measured lesion. 
Results: As expected, when independent radiology review was 
conducted using RECIST criteria, similar overall response rates were 
conﬁrmed, although individual patients’ response may have changed. 
Signiﬁcant cavitation of pulmonary lesions was seen in approximately 
20% of patients treated with VEGFR inhibitors. The use of the ‘explor-
atory’ response assessment did not signiﬁcantly increase the overall 
number of responses but did lead to an earlier designation of response 
and/or progression in 10% of patients.
Conclusions: The addition of VEGFR inhibitors to platinum-based 
chemotherapy leads to encouraging antitumour activity, sometimes 
with cavitation. The cavitation noted with the use of antiangiogenic 
agents may have implications for response assessment and trial end-
points that rely upon determination of time to disease progression. 
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Background: C225 is a unique monoclonal antibody targeting epidermal 
growth factor receptor. Weekly C225 in combination with standard q 3 
week PacCb yielded a median survival of nearly 11 months in a large 
phase II trial of SWOG (Kelly, ASCO 2006), and is currently being test-
ed in combination with bevacizumab and PacCb. We mounted a phase II 
trial of this agent in combination with monthly Cb and weekly Pac, in an 
effort to capitalize on potential synergy between taxane and C225, and to 
mitigate taxane-induced neuropathy and myalgia/arthralgias. 
